| ¿µ¹® | dopamine | ÇÑ±Û | µµÆÄ¹Î |
|---|---|---|---|
| ¼³¸í | È÷µå·Ï½ÃƼ¶ó¹ÎÀ¸·Î¼ »ý¸®È°¼º ¾Æ¹Î-Ä«Å×ÄݾƹÎÀÇ ÀÏÁ¾. ºÐÀÚ½ÄÀºC18H11NO2, ºÐÀÚ·®Àº 153.18ÀÌ´Ù. µ¿½Ä¹°¿¡ Á¸ÀçÇÏ´Â ¾Æ¹Ì³ë»êÀÇ Çϳª·Î, Àڿܼ± ÀÛ¿ëÀ¸·Î Ƽ·Î½Å¿¡¼ Çü¼ºµÇ°Å³ª L-DopaÀÇ Å»Åº»ê¿¡ ÀÇÇØ ü³»¿¡¼ »ý»êµÈ´Ù. ¸á¶ó´Ñ »ö¼Ò ÇÕ¼º °úÁ¤ÀÇ Áß°£ ¹°Áú·Î Äá°ú ½Ä¹°¿¡ ÀúÀåµÇ¾î ÀÖ´Ù. ³ú½Å°æ ¼¼Æ÷ÀÇ ÈïºÐ Àü´Þ¿¡ Áß¿äÇÑ ±¸½ÇÀ» ÇÑ´Ù. µµÆÄ¹Î¥â-»êÈÈ¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ³ë¸£¾Æµå·¹³¯¸°ÀÌ µÈ´Ù. ºÎ½Å¼öÁú-³ú-±³°¨½Å°æ°è-Æó-ÀÛÀºÃ¢ÀÚ-°£ µî¿¡µµ ¸¹ÀÌ Æ÷ÇԵǾî ÀÖ´Ù. ÆÄŲ½¼ ÁõÈıºÀÇ °æ¿ì ³ú ¾ÈÀÇ µµÆÄ¹Î ·®ÀÌ °¨¼ÒµÇ¸ç, ³úÁÙ±âÀÇ ÁÙ¹«´Ìü¿¡´Â ³ë¸£¾Æµå·¹³¯¸°º¸´Ù µµÆÄ¹ÎÀÌ ´Ù·® Æ÷ÇԵǾî ÀÖÀ½À» º¼ ¼ö ÀÖ´Ù´Â Á¡¿¡¼ µµÆÄ¹Î ÀÚü°¡ À̸¥¹Ù Ä«Å×ÄݾƹÎÀ» ÇÔÀ¯ÇÏ´Â ÀÛµ¿¼º ´º·±ÀÇ ½Å°æÀü´Þ¹°Áú·Î¼ ÀÛ¿ëÇϰí ÀÖÀ½ÀÌ ºÐ¸íÇØÁ³´Ù. |
||
| AChRs | Acetylcholine Receptors |
|---|---|
| RA | radioactive; ragocyte; ragweed antigen; rapidly adapting [receptors]; reactive arthritis; reciprocal... |
| DBH | Dopamine-Beta(¥â)-Hydroxylase |
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| DBH | dopamine beta-hydroxylase |
| DA | 14C-dopamine |
|---|---|
| DA | 3)H]-dopamine |
| [(3)H]-DA | 3)H]-dopamine |
| dopamine | 3,4-Dihydroxyphenylethylamine |
| D1R | D1 dopamine receptor |
striate body neurosis
| receptors, dopamine | Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
|---|---|
| receptors, dopamine d1 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, by their mode of action. (12 Dec 1998) |
| receptors, dopamine d2 | A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action. (12 Dec 1998) |
| dopamine | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| dopamine agonists | Drugs that bind to and activate dopamine receptors. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| dopamine beta-hydroxylase | <enzyme> Chemical name: 3,4-Dihydroxyphenethylamine, ascorbate:oxygen oxidoreductase (beta-hydroxylating) Registry number: EC 1.14.17.1 (12 Dec 1998) |
| dopamine beta-monooxygenase | A copper-containing enzyme catalyzing oxidation of ascorbate and 3,4-dihydroxyphenylethylamine simultaneously by O2 to yield norepinephrine, dehydroascorbate, and water; a crucial step in catecholamine metabolism. Synonym: dopamine beta-hydroxylase. (05 Mar 2000) |
| dopamine hydrochloride | A biogenic amine and neural transmitter substance, used as a vasopressor agent for treatment of shock. (05 Mar 2000) |
| dopamine uptake inhibitors | Drugs that block the transport of dopamine into axon terminals or into storage vesicles within terminals. most of the adrenergic uptake inhibitors also inhibit dopamine uptake. (12 Dec 1998) |
| adrenergic receptors | Reactive components of effector tissues, most of which are innervated by adrenergic postganglionic fibres of the sympathetic nervous system. Such receptor's can be activated by norepinephrine and/or epinephrine and by various adrenergic drugs; receptor activation results in a change in effector tissue function, such as contraction of arteriolar muscles or relaxation of bronchial muscles; adrenergic receptor's are divided into alpha-receptor's and beta-receptor's, on the basis of their response to various adrenergic activating and blocking agents. Synonym: adrenoceptor, adrenoreceptors. (05 Mar 2000) |
| alpha-adrenergic receptors | Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles. (05 Mar 2000) |
| ANP clearance receptors | Cell surface proteins that bind atrial natriuretic peptide and ANP fragments without initiating biological action. (05 Mar 2000) |
| ANP receptors | Cell surface receptors for atrial natriuretic peptide that have a single transmembrane spanning element; these have integral kinase and guanylate cyclase domains. (05 Mar 2000) |
Synonyms : Dopamine D3 Receptor, Receptor, Dopamine-D3, D3 Receptor, Dopamine, D3 Receptors, Dopamine, Dopamine-D3 Receptor, Receptor, Dopamine D3
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|